Passage Bio Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Will Chou

Chief Executive Officer (CEO)

US$1.4m

Compensación total

Porcentaje del salario del CEO	41.4%
Permanencia del CEO	1.6yrs
Participación del CEO	n/a
Permanencia media de la dirección	1.2yrs
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Passage Bio partners with InformedDNA to offer counseling, testing for early dementia

May 03

We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Mar 08

Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

Feb 01

Passage Bio on go with PBGM01 gene therapy trial in the U.S.

Jan 04

Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares

Dec 28

U.K. authorizes Passage Bio's PBGM01 trial

Dec 10

Passage Bio (PASG) Investor Presentation - Slideshow

Nov 16

Passage Bio EPS beats by $0.13

Nov 10

Passage Bio’s PBKR03 nabs Orphan drug tag and accelerated review status for Krabbe disease

Oct 28

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Will Chou en comparación con los beneficios de Passage Bio?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$1m	US$599k	-US$102m
Sep 30 2023	n/a	n/a	-US$112m
Jun 30 2023	n/a	n/a	-US$112m
Mar 31 2023	n/a	n/a	-US$128m
Dec 31 2022	US$1m	US$112k	-US$136m

Compensación vs. Mercado: La compensación total de Will($USD1.45M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Will ha aumentado mientras la empresa no es rentable.

CEO

Will Chou (49 yo)

1.6yrs

Permanencia

US$1,448,546

Compensación

Dr. William Chou, MD, also known as Will, has been the Chief Executive Officer and Director of Passage Bio, Inc. from October 10, 2022 and serves as its President. Dr. Chou is an accomplished executive wit...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
William Chou	President	1.6yrs	US$1.45m	sin datos
Edgar Cale	General Counsel & Company Secretary	4.7yrs	US$804.69k	0.080% $ 63.8k
Mark Forman	Chief Medical Officer	2.8yrs	US$1.01m	0.079% $ 62.7k
James Wilson	Co-Founder & Chief Scientific Advisor	no data	sin datos	sin datos
Kathleen Borthwick	Senior VP	less than a year	sin datos	0.046% $ 36.7k
Stuart Henderson	Senior Vice President of Corporate Development & Investor Relations	3.3yrs	sin datos	sin datos
Eden Fucci	Senior Vice President of Technical Operations	less than a year	sin datos	sin datos
Sue Browne	Senior Vice President of Research & Development	less than a year	sin datos	sin datos
Karl Whitney	Senior Vice President of Global Regulatory Affairs	less than a year	sin datos	sin datos

1.2yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PASG no se considera experimentado ( 1.1 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
William Chou	President	1.6yrs	US$1.45m	sin datos
Maxine Gowen	Independent Chairwoman of the Board	3.3yrs	US$101.34k	0% $ 0
Saqib Islam	Independent Director	5.2yrs	US$65.84k	0.0081% $ 6.5k
Athena Countouriotis	Independent Director	4.3yrs	US$79.84k	0.031% $ 24.4k
Sandip Kapadia	Independent Director	4.4yrs	US$73.34k	0% $ 0
Derrell Porter	Independent Director	3yrs	US$69.30k	0% $ 0
Dolan Sondhi	Independent Director	less than a year	US$49.90k	0% $ 0

3.3yrs

Permanencia media

52yo

Promedio de edad

Junta con experiencia: La junta directiva de PASG se considera experimentada (3.2 años de antigüedad promedio).

Passage Bio Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Passage Bio, Inc., Annual General Meeting, May 21, 2024

Passage Bio, Inc. Announces Executive Changes

High number of new directors

Passage Bio, Inc. Announces Resignation of Maxine Gowen as Interim Executive Chairwoman

Passage Bio, Inc. Announces Executive Changes

High number of new directors

Recent updates

New minor risk - Shareholder dilution

Passage Bio, Inc., Annual General Meeting, May 21, 2024

Passage Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Price target increased by 27% to US$7.00

Passage Bio, Inc. Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Price target decreased by 23% to US$5.40

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. Receives Non-Compliance Notice From Nasdaq

Passage Bio, Inc. Receives Non-Compliance Notice From Nasdaq

Price target decreased by 20% to US$7.00

Passage Bio, Inc. Announces New Interim Safety, Biomarker, and Survival Data from Cohorts 1-4 in Imagine-1 Clinical Study

Passage Bio, Inc. Announces Executive Changes

Price target increased by 9.9% to US$8.17

We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

Price target increased by 9.3% to US$8.33

Passage Bio, Inc. Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

High number of new directors

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. Announces Resignation of Maxine Gowen as Interim Executive Chairwoman

Passage Bio, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Passage Bio, Inc. Announces Executive Changes

Passage appoints William Chou CEO

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

Passage Bio GAAP EPS of -$0.73 beats by $0.09

High number of new directors

Passage Bio, Inc. Appoints Michael Kamarck to Board of Directors

Passage Bio, Inc.(NasdaqGS:PASG) dropped from Russell 2000 Dynamic Index

Passage Bio, Inc. Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy

We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Passage Bio, Inc. Announces Management Changes

Passage Bio, Inc. Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study At ASGCT 25Th Annual Meeting

Passage Bio, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new directors

Passage Bio, Inc., Annual General Meeting, May 26, 2022

Passage Bio: Worth Keeping An Eye On

Passage Bio, Inc. Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease

Passage Bio, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Passage Bio Presents New Interim Clinical Data for Patients with Gm1 Gangliosidosis in Imagine-1 Study At 2022 Worldsymposium

Price target decreased to US$23.38

Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Passage Bio Announces Pipeline Expansion and Clinical Program Update

Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

Passage Bio, Inc.(NasdaqGS:PASG) dropped from Russell 2500 Growth Index

Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing

Independent Director Patrick Heron has left the company

Chief Financial Officer has left the company

Chief Medical Officer has left the company

Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting

Passage Bio partners with InformedDNA to offer counseling, testing for early dementia

Chief Medical Officer notifies of intention to sell stock

Passage Bio, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates Targeting Rare CNS Disorders

We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Passage Bio, Inc. to Report Q4, 2020 Results on Mar 03, 2021

New 90-day low: US$18.13

Passage Bio, Inc. Announces Board Changes

FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease

Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

Passage Bio, Inc. Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations

Chief Operating Officer notifies of intention to sell stock

New 90-day high: US$29.83

Passage Bio, Inc. Announces Update on Significant Pipeline and Corporate Advancement

Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis

Passage Bio on go with PBGM01 gene therapy trial in the U.S.

Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares

New 90-day high: US$29.73